Open-label, non-randomized, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) as a part of combination therapy in participants with locally advanced and unresectable or metastatic MSI-H/dMMR gastroesophageal junction /gastric cancer.’
Abierta
- Código protocolo: CL1-95029-002
- Código EudraCT: No aplica
- Grupo de investigación: Investigación Biomédica en Tumores del Aparato Digestivo
- Servicio: Oncología
- Investigador/a principal: Acosta Eyzaguirre, Daniel
- Patología: Tumors
- Fase: Fase I
- Estado: Reclutando voluntarios